The following biotech stocks touched a new 52-week high yesterday.
AVEO Pharmaceuticals Inc. (AVEO) is just one step away from getting a U.S. patent for the use of its lead product Fotivda for the treatment of refractory advanced renal cell carcinoma. Shares touched a 52-week intraday high of $9.62 yesterday.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com